Therapeutic Outlook in DLBCL: Evaluating Treatment Sequencing from Front-line to Relapsed Refractory Disease - Episode 11
Additional Perspectives Beyond CAR T-cell Regimens in Relapsed/Refractory DLBCL.: Bispecifics
A discussion of current trials on bispecific antibody therapies in DLBCL, highlighting key takeaways from STARGLO on Glofit+GemOx in relapsed/refractory disease, the potential role of bispecifics in second-line treatment, and the patient populations and care settings most likely to benefit from these emerging options.
Video content above is prompted by the following:
Please discuss current trials using bispecific antibody therapies in DLBCL.
- What are key takeaways from Glofit + GemOx in RR DLBCL (STARGLO: Gregory et al. ASH 2024). How do you foresee these results impacting future treatment choices?
- What other emerging bispecific antibody therapy 2L trials are you excited about?
- Do you see a space for bispecific antibody therapy in 2L? If so, what patients do you think would most benefit from this potentially new option?
- Please comment on patient population and sites of care that would most benefit from bispecific antibodies in 2L.